
News|Videos|August 1, 2024
Emerging Treatments in Mild/Moderate Multiple Sclerosis
Key opinion leaders examine the available data on Bruton tyrosine kinase (BTK) inhibitors to assess whether the evidence supports their efficacy as a treatment option for multiple sclerosis (MS).
Advertisement
Episodes in this series

BTK inhibitors: Do the current data suggest this strategy for mild MS?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Clears Phase 2a Clinical Trial to Test JOTROL in Patients With Parkinson Disease
2
Fenebrutinib Hits Key Phase 3 Marks in Relapsing and Primary Progressive MS
3
OnabotulinumtoxinA Fails to Meet Primary End Point in Phase 3 PRECLUDE Trial for Episodic Migraine
4
Doxecitine/Doxribitine Approval Redefines Care in Thymidine Kinase 2 Deficiency: Fabian Somers, PhD
5































